• Explore /
  • Poster
  • / Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

Abstract Video & Slides Poster

Authors

null

Richard S. Finn

Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles, CA

Richard S. Finn , Shukui Qin , Masafumi Ikeda , Peter R. Galle , Michel Ducreux , Tae-You Kim , Masatoshi Kudo , Ho Yeong Lim , Valeriy Vladimirovich Breder , Philippe Merle , Ahmed Omar Kaseb , Daneng Li , Yin-Hsun Feng , Wendy Verret , Derek-Zhen Xu , Sairy Hernandez , Beiying Ding , Andrew X. Zhu , Ann-Lii Cheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03434379

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4596)

DOI

10.1200/JCO.2020.38.15_suppl.4596

Abstract #

4596

Poster Bd #

204

Abstract Disclosures

Similar Posters

First Author: Michel Ducreux

First Author: Richard S. Finn

First Author: Han Chong Toh

First Author: Masatoshi Kudo